DOCS
VENTE TOTALE: 11 500 titres (~395 885,00 $ US)
- Insiders
- Wampler Kira Scherer, Cabral Timothy S
- Total bought
- —
- Total sold
- $395,885
- Last activity
- 2026-09-01
- Last synced
-
2026-09-07 10:23:47
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-09-05
DOCS presents an exceptionally strong balance sheet and liquidity profile (score: 95), but the weak catalyst score (20) with no identifiable near-term event driver significantly limits the upside thesis.
The first sentence of the analysis written for DOCS on 2026-09-05 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 89.1% | 90.2% | 89.3% | 87.2% | 88.4% | |
| Ebit Margin | 38.8% | 40.3% | 36.1% | 31.8% | 33.2% | |
| Ebitda Margin | 41.0% | 42.2% | 38.3% | 34.2% | 34.7% | |
| Operating Profit Margin | 33.3% | 39.9% | 34.5% | 29.9% | 33.0% | |
| Pretax Profit Margin | 38.8% | 46.2% | 39.0% | 31.8% | 33.2% | |
| Continuous Operations Profit Margin | 30.4% | 39.1% | 31.0% | 26.9% | 45.1% | |
| Net Profit Margin | 30.4% | 39.1% | 31.0% | 26.9% | 45.1% | |
| Bottom Line Profit Margin | 30.4% | 39.1% | 31.0% | 26.9% | 38.8% | |
| Current Ratio | 6.093 | 6.967 | 6.200 | 6.992 | 8.125 | |
| Quick Ratio | 6.093 | 6.967 | 6.200 | 6.992 | 8.125 | |
| Solvency Ratio | 1.217 | 1.287 | 0.887 | 0.721 | 1.417 | |
| Cash Ratio | 1.414 | 1.341 | 0.657 | 1.133 | 1.014 | |
| Price To Earnings Ratio | 22.190 | 48.765 | 33.859 | 55.828 | 64.309 | |
| Price To Earnings Growth Ratio | -1.886 | 0.928 | 0.982 | -1.966 | 0.112 | |
| Forward Price To Earnings Growth Ratio | -1.886 | 0.928 | 0.982 | -1.966 | 0.112 | |
| Price To Earnings Diluted Ratio | 23.776 | 52.279 | 36.681 | 61.094 | 74.414 | |
| Price To Earnings Diluted Growth Ratio | -2.030 | 0.965 | 1.023 | -2.516 | 0.154 | |
| Price To Book Ratio | 4.583 | 10.015 | 5.572 | 6.474 | 9.693 | |
| Price To Sales Ratio | 6.757 | 19.008 | 10.564 | 14.927 | 24.788 | |
| Price To Free Cash Flow Ratio | 13.724 | 40.648 | 28.169 | 36.069 | 70.450 | |
| Price To Operating Cash Flow Ratio | 13.348 | 39.677 | 27.282 | 34.827 | 67.279 | |
| Debt To Assets Ratio | 0.009 | 0.010 | 0.013 | 0.014 | 0.001 | |
| Debt To Equity Ratio | 0.011 | 0.011 | 0.016 | 0.016 | 0.001 | |
| Debt To Capital Ratio | 0.011 | 0.011 | 0.016 | 0.016 | 0.001 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.182 | 1.168 | 1.197 | 1.177 | 1.128 | |
| Working Capital Turnover Ratio | 0.749 | 0.672 | 0.594 | 0.515 | 0.763 | |
| Operating Cash Flow Ratio | 2.107 | 1.749 | 1.250 | 1.287 | 1.137 | |
| Operating Cash Flow Sales Ratio | 0.506 | 0.479 | 0.387 | 0.429 | 0.368 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.973 | 0.976 | 0.968 | 0.966 | 0.955 | |
| Debt Service Coverage Ratio | 99.732 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 154.719 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 32.053 | 22.045 | 12.656 | 11.486 | 116.230 | |
| Capital Expenditure Coverage Ratio | 36.423 | 41.880 | 31.735 | 29.043 | 22.218 | |
| Dividend Paid And Capex Coverage Ratio | 36.423 | 41.880 | 31.735 | 29.043 | 22.218 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 15.691 | 44.214 | 27.132 | 42.615 | 70.597 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 89.1% | ▼-1.1% | ▲0.2% |
| Ebit Margin | 38.8% | ▼-1.6% | ▲2.7% |
| Ebitda Margin | 41.0% | ▼-1.2% | ▲2.9% |
| Operating Profit Margin | 33.3% | ▼-6.6% | ▼-0.8% |
| Pretax Profit Margin | 38.8% | ▼-7.4% | ▲1.0% |
| Continuous Operations Profit Margin | 30.4% | ▼-8.7% | ▼-4.1% |
| Net Profit Margin | 30.4% | ▼-8.7% | ▼-4.1% |
| Bottom Line Profit Margin | 30.4% | ▼-8.7% | ▼-2.9% |
| Current Ratio | 6.093 | ▼-0.874 | ▼-0.782 |
| Quick Ratio | 6.093 | ▼-0.874 | ▼-0.782 |
| Solvency Ratio | 1.217 | ▼-0.070 | ▲0.112 |
| Cash Ratio | 1.414 | ▲0.073 | ▲0.302 |
| Price To Earnings Ratio | 22.191 | ▼-26.574 | ▼-22.800 |
| Price To Earnings Growth Ratio | -1.886 | ▼-2.814 | ▼-1.520 |
| Forward Price To Earnings Growth Ratio | -1.886 | ▼-2.814 | ▼-1.520 |
| Price To Earnings Diluted Ratio | 23.776 | ▼-28.504 | ▼-25.873 |
| Price To Earnings Diluted Growth Ratio | -2.030 | ▼-2.995 | ▼-1.549 |
| Price To Book Ratio | 4.583 | ▼-5.432 | ▼-2.685 |
| Price To Sales Ratio | 6.757 | ▼-12.251 | ▼-8.452 |
| Price To Free Cash Flow Ratio | 13.724 | ▼-26.923 | ▼-24.088 |
| Price To Operating Cash Flow Ratio | 13.348 | ▼-26.330 | ▼-23.135 |
| Debt To Assets Ratio | 0.009 | ▼-0.001 | ▼-0.000 |
| Debt To Equity Ratio | 0.011 | ▼-0.001 | ▼-0.000 |
| Debt To Capital Ratio | 0.011 | ▼-0.001 | ▼-0.000 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.182 | ▲0.014 | ▲0.011 |
| Working Capital Turnover Ratio | 0.749 | ▲0.077 | ▲0.091 |
| Operating Cash Flow Ratio | 2.107 | ▲0.358 | ▲0.601 |
| Operating Cash Flow Sales Ratio | 0.506 | ▲0.027 | ▲0.072 |
| Free Cash Flow Operating Cash Flow Ratio | 0.973 | ▼-0.004 | ▲0.005 |
| Debt Service Coverage Ratio | 99.732 | ▲99.732 | ▲79.785 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 154.719 | ▲154.719 | ▲123.775 |
| Operating Cash Flow Coverage Ratio | 32.053 | ▲10.008 | ▼-6.841 |
| Capital Expenditure Coverage Ratio | 36.423 | ▼-5.457 | ▲4.163 |
| Dividend Paid And Capex Coverage Ratio | 36.423 | ▼-5.457 | ▲4.163 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 15.691 | ▼-28.524 | ▼-24.359 |
Key metrics
| Metric | Trend | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|---|
| Market cap | $4.36B | $10.84B | $5.02B | $6.26B | $8.52B | |
| Enterprise value | $4.15B | $10.65B | $4.94B | $6.11B | $8.40B | |
| EV / Sales | 6.43x | 18.66x | 10.39x | 14.59x | 24.46x | |
| EV / Op. cash flow | 12.71x | 38.95x | 26.84x | 34.03x | 66.40x | |
| EV / Free cash flow | 13.07x | 39.91x | 27.71x | 35.25x | 69.53x | |
| EV / EBITDA | 15.69x | 44.21x | 27.13x | 42.62x | 70.60x | |
| Net debt / EBITDA | -0.79x | -0.82x | -0.45x | -0.99x | -0.94x | |
| Current ratio | 6.09x | 6.97x | 6.20x | 6.99x | 8.12x | |
| Income quality | 1.67x | 1.22x | 1.25x | 1.59x | 0.82x | |
| Graham number | $11 | $12 | $9 | $8 | $11 | |
| Graham net-net | $4 | $4 | $3 | $4 | $5 | |
| Tax burden | 78.4% | 84.7% | 79.7% | 84.7% | 135.8% | |
| Interest burden | 100.0% | 114.5% | 107.8% | 100.0% | 100.0% | |
| Working capital | $789.3M | $932.4M | $765.7M | $835.9M | $792.9M | |
| Invested capital | $934.8M | $1.05B | $885.6M | $960.8M | $829.3M | |
| Return on assets | 17.4% | 17.7% | 13.7% | 9.9% | 15.6% | |
| Operating ROA | 18.0% | 19.4% | 14.8% | 11.8% | 18.3% | |
| Return on tangible assets | 19.5% | 19.0% | 15.0% | 10.9% | 16.0% | |
| Return on equity | 20.6% | 20.6% | 16.4% | 11.7% | 17.6% | |
| Return on invested capital | 17.4% | 17.4% | 14.0% | 10.6% | 12.9% | |
| Return on capital employed | 22.2% | 20.6% | 17.6% | 12.5% | 12.9% | |
| Earnings yield | 4.5% | 2.1% | 2.9% | 1.8% | 1.8% | |
| Free cash flow yield | 7.3% | 2.5% | 3.5% | 2.8% | 1.4% | |
| Capex / Op. cash flow | 2.7% | 2.4% | 3.2% | 3.4% | 4.5% | |
| Capex / Depreciation | 62.3% | 61.2% | 56.5% | 60.1% | 113.0% | |
| Capex / Sales | 1.4% | 1.1% | 1.2% | 1.5% | 1.7% | |
| SG&A / Sales | 35.5% | 33.6% | 36.0% | 38.2% | 37.2% | |
| R&D / Sales | 20.3% | 16.3% | 17.2% | 19.1% | 18.1% | |
| Stock comp / Sales | 18.9% | 12.7% | 10.7% | 11.4% | 9.2% | |
| Intangibles / Total assets | 10.7% | 7.2% | 8.8% | 8.8% | 2.7% | |
| Days sales outstanding | 82d | 82d | 78d | 93d | 86d | |
| Days payables outstanding | 21d | 9d | 16d | 9d | 4d | |
| Operating cycle | 82d | 82d | 78d | 93d | 86d | |
| Cash conversion cycle | 61d | 73d | 62d | 85d | 82d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-59.8%EV / Sales ▼-65.5%EV / EBITDA ▼-64.5%EV / Op. cash flow ▼-26.248Earnings yield ▲+0.024Graham number ▼-1.528
Profitability
Return on equity +0.000Return on assets ▼-0.002Return on invested capital -0.000Return on capital employed ▲+0.016Operating ROA ▼-0.014Income quality ▲+0.441Tax burden ▼-0.063
Efficiency
Days sales outstanding ▼-0.185Days payables outstanding ▲+11.949Operating cycle ▼-0.185Cash conversion cycle ▼-12.134Capex / Sales ▲+0.002R&D / Sales ▲+0.040
Balance-sheet strength
Current ratio ▼-0.874Net debt / EBITDA ▲+0.029Working capital ▼-143072000.000Invested capital ▼-111108000.000Intangibles / Total assets ▲+0.035
Change over 5 years
Valuation
Market cap ▼-48.8%EV / Sales ▼-73.7%EV / EBITDA ▼-77.8%EV / Op. cash flow ▼-53.689Earnings yield ▲+0.027Graham number ▲+0.251
Profitability
Return on equity ▲+0.030Return on assets ▲+0.018Return on invested capital ▲+0.045Return on capital employed ▲+0.093Operating ROA ▼-0.003Income quality ▲+0.847Tax burden ▼-0.573
Efficiency
Days sales outstanding ▼-4.187Days payables outstanding ▲+16.560Operating cycle ▼-4.187Cash conversion cycle ▼-20.746Capex / Sales ▼-0.003R&D / Sales ▲+0.021
Balance-sheet strength
Current ratio ▼-2.032Net debt / EBITDA ▲+0.148Working capital ▼-3564000.000Invested capital ▲+105555000.000Intangibles / Total assets ▲+0.080
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2025-11-06 | Jonathan Jackson | Sale | $15,001 - $50,000 |
| 2025-08-25 | Jonathan Jackson | Purchase | $15,001 - $50,000 |
Recent news
- 2026-09-04 AXQ Capital LP Has $3.67 Million Stake in Doximity, Inc. $DOCS AXQ Capital LP grew its stake in shares of Doximity, Inc. (NYSE: DOCS) by 1,354.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 177,044 shares of the company''s stock after buying an additional 164,872 shares during the period. AXQ
- 2026-08-28 Doximity Inc (DOCS) Shares Surge 4.5% -- What GF Score of 86 Tells Investors On August 28, 2026, Doximity Inc (DOCS) shares rose 4.5% to a current price of $26.73. This performance occurred amidst a 52-week range of $17.15 to $76.51, ind
- 2026-08-27 Doximity Inc (DOCS) Shares Surge 3.4% -- What GF Score of 82 Tells Investors On August 27, 2026, Doximity Inc (DOCS) shares rose 3.4% to a current price of $25.59, reflecting a significant shift amidst a 52-week range of $17.15 to $76.51
- 2026-08-27 Financial Contrast: Doximity (NYSE:DOCS) and MedPeer,Inc. (OTCMKTS:MDPEF) MedPeer,Inc. (OTCMKTS:MDPEF - Get Free Report) and Doximity (NYSE: DOCS - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, dividends and analyst recommendations. Earnings and Valuation This table compares MedPeer,Inc. and Doximity"s gross
- 2026-08-25 Overworked Doctors Bet on AI to Boost Their Pay [url="]Doximity[/url], Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced new data indicating that physicians are f
- 2026-08-25 Overworked Doctors Bet on AI to Boost Their Pay SAN FRANCISCO--(BUSINESS WIRE)--Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced new data indicating that physicians are finding an unexpected source of optimism in AI. Rather than viewing the technology as a threat, nearly a quarter expect it to increase their total compensation within the next year, and two-thirds believe staying current with AI will give them a meaningful earnings edge over peers who don''t. The findings are part of Dox.
- 2026-08-24 Reasons to Retain Doximity Stock in Your Portfolio for Now DOCS'' AI expansion is opening new growth avenues, but rising AI costs and tight pharma budgets could temper near-term gains.
- 2026-08-18 A Doximity Director Moved 7,500 Shares the Day the Stock Popped 33%. Here''s What to Know This sale was executed under a pre-established Rule 10b5-1 trading plan adopted in February.
- 2026-08-18 What Investors Should Know of This Doximity Officer''s Latest Insider Transaction The transaction involved the exercise of options and a subsequent disposition valued at $140,400 at $24.84 per share. The activity was split between a Rule 10b5-1 trading plan sale to cover tax obligations and mandated shares withheld by the issuer for restricted stock unit vesting.
- 2026-08-18 Doximity Handed Its President 150,000 Options Last Month. Here''s What the Latest Filing Signals for Investors The shares traded represent about $111,154 in total value based on the execution price on August 15. This disposition reduced the insider''s direct equity holdings by 8%.